What happened with PACB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pacific Biosciences of California, known as PacBio, helps research institutions, testing laboratories and pharmaceutical and agricultural companies analyze genetic material. Its HiFi technology reads long stretches of DNA with high accuracy, supporting work such as genome analysis, rare-disease research and crop research.
Customers buy Revio and Vega sequencing instruments, then purchase proprietary SMRT Cell chips and reagent kits as they process samples. These consumables are its largest revenue source, ahead of instruments; service contracts and other services contribute a smaller share. The business therefore depends both on laboratories buying systems and on how much they use them afterward.
A significant share of revenue comes from a limited group of customers, many placing large orders rather than buying under long-term contracts. Equipment purchases depend heavily on customer budgets, including government research funding. PacBio also relies on a Taiwan-based company for part of the manufacturing of substantially all its consumable chips. It currently markets its products for research use only, not for clinical diagnostic tests or as medical devices; marketing them for diagnostic use could require regulatory clearance or approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
PacBio’s results hinge on research funding, sequencing use and long-read adoption, making Oxford Nanopore Technologies an important competitor to watch beyond this list.
Illumina competes with PacBio for sequencing budgets at genomic research centers and clinical laboratories, selling both instruments and the proprietary supplies used on them. Watch Illumina’s sequencing consumable sales for signs of laboratory activity and competition for that spending.
Bionano Genomics offers research and clinical laboratories an alternative to PacBio’s HiFi sequencing for detecting structural changes in DNA: systems that build physical genome maps, called optical genome mapping. Its Saphyr and Stratys system and consumable sales show demand for that alternative.
10x Genomics and PacBio share exposure to academic genomics funding: overlapping research institutions buy 10x’s single-cell instruments and consumables and PacBio’s sequencing platforms and RNA kits. Watch demand for 10x’s Chromium consumables as a sign of spending on single-cell research workflows.
Thermo Fisher Scientific competes with PacBio by selling sequencing equipment and consumables to research and clinical laboratories. Sequencing is only part of Thermo Fisher’s broader laboratory and pharmaceutical-services business, so its sequencing offerings matter more to this rivalry than its overall results.
QIAGEN competes with PacBio for research and molecular-testing laboratories’ spending on supplies and workflows that prepare samples and analyze molecular information. Watch QIAGEN’s consumables and related revenue, rather than just instrument sales, for demand in this overlapping area.
Twist Bioscience and PacBio both benefit from growing genomic experiment volumes: Twist sells laboratories products that select DNA regions for sequencing, while PacBio sells sequencing instruments and consumables. Twist’s sequencing target-enrichment business is the part to watch for this shared demand.
Illumina Inc earningsILMN
Illumina’s report will show whether genomic research centers and clinical labs are still spending on sequencing instruments and proprietary supplies—the same budgets PacBio competes for.
Watch Illumina’s sequencing consumables sales. Resilient sales would show that labs are active and buying supplies, while also confirming Illumina remains a strong rival for PacBio’s sequencing budgets. Weak sales would point to softer demand in this shared market, not prove that PacBio is taking share.
Pacific Biosciences of California, Inc. earningsThis company
PacBio’s report will show whether consumables and service revenue from its installed systems can offset slower instrument sales.
Read consumables and service revenue alongside Revio and Vega instrument sales. Growth in recurring sales with resilient instrument sales would show that existing customers keep using PacBio systems while new customers buy them; weak recurring sales and continued instrument softness would show that the installed base is not yet generating enough repeat business to offset delayed equipment purchases.
10x Genomics, Inc. earningsTXG
10x Genomics’ report will show whether research institutions are still buying supplies for single-cell workflows, a clue to spending by the academic customers PacBio also serves.
Watch demand for 10x Genomics’ Chromium consumables. Resilient demand would show that shared academic customers are still funding single-cell research, activity that can also generate demand for PacBio sequencing. Weak demand would point to pressure on these customers’ research spending, not establish that they will redirect budgets to PacBio.
Bionano Genomics, Inc. earningsBNGO
Bionano Genomics’ report will show whether labs are buying optical genome mapping as an alternative for detecting structural DNA changes, a specific area where it competes with PacBio HiFi sequencing.
Read Bionano Genomics’ Saphyr and Stratys system sales alongside consumables sales. Strength in both would show labs are adopting this alternative for structural-variant work, making competition with PacBio’s HiFi systems more tangible; weakness in both would show limited uptake, not prove customers chose PacBio instead.
Twist Bioscience Corporation earningsTWST
Twist Bioscience’s report will show whether labs are buying products that prepare selected DNA regions for sequencing, a signal of genomic research activity that can also support PacBio’s business.
Watch demand in Twist Bioscience’s sequencing target-enrichment business. Strong demand would show labs are continuing experiments that select DNA regions for sequencing, activity that can also support use of PacBio systems. Weak demand would suggest those experiments are slowing or constrained, but would not by itself establish a change in PacBio sequencing volume.
